“The third quarter of 2015 was the first full quarter of PersonalizeDx
being part of Rosetta Genomics and we had strong revenue growth from our
two lines of business, namely solid tumor testing services and urologic
cancer testing services.

“Throughout the third quarter and recent weeks we have been focused on
the preparation and launch of RosettaGX Reveal, our microRNA-based assay
for the classification of indeterminate thyroid nodules. We are
particularly excited about the positive performance data from our
blinded validation study of RosettaGX Reveal as these data demonstrate
exceptional clinical performance when compared with the current market
leader. The ability to run RosettaGX Reveal on cytology slides is
important because working off the same slides created to perform the
initial diagnoses eliminates the inconvenience and risks associated with
additional fine needle passages into the patient’s neck that are
required by other assays. We have already begun to receive and process
commercial samples at our Philadelphia laboratory and have reported our
results on these first orders with very positive feedback from
clinicians. Moving forward, our plan is to leverage our solid tumor
sales force as well as a dedicated group of thyroid sales specialists to
call on endocrinologists and cytopathologists to form a third business
segment with high-growth potential. Given its high negative predictive
value, health economic benefit and added convenience of working on
cytology slides, we expect RosettaGX Reveal to gain significant traction
into a market valued at $350 million annually in the U.S.

“When issued, our new U.S. patent in prostate cancer will fortify our
leadership in microRNA technology and expand our footprint in urological
cancers. Through PersonalizeDx we offer FISH, IHC and PCR-based testing
capabilities in urologic and other cancers, which provide content and
platforms that complement our microRNA offerings to provide clinicians
with valuable information to guide treatment decisions. This patent is
important as this biomarker, which is over-expressed in primary prostate
tumors, could be used as both a prognostic tool and as a therapeutic
target for prostate cancer. We continue to explore opportunities to
monetize our broad intellectual property portfolio in microRNA-based
diagnostics and therapeutics.

“We were particularly pleased with the recent Clinical Lab Fee Schedule
(CLFS) posted by the Centers for Medicare and Medicaid Services (CMS)
for 2016, which reverses some of the unfavorable features of the
original CLFS draft proposal. Importantly, the final fees provide a long
overdue correction to FISH reimbursement, which includes a 92% increase
in allowable reimbursement for our most common solid tumor FISH
procedures, which account for approximately 20% of our current testing
revenue. These and other favorable fee schedules are encouraging and
should continue to enhance both the amount and timing of payments for
our testing services in 2016.

“As we look toward 2016, Rosetta Genomics is fundamentally stronger and
better positioned for success, and we look forward to achieving a series
of value-creating milestones,” concluded Mr. Berlin.

Financial results for the three months ended September 30, 2015
include:

The Company recorded revenues from continuing operations for the third
quarter of 2015 of $2.4 million, up 790% from revenues from continuing
operations of $273,000 for the third quarter of 2014 and up 17% from
pro forma revenues from continuing operations of $2.1 million for the
second quarter of 2015.

Revenue from solid tumor testing services in the third quarter of 2015
increased 319% to $1.1 million from $273,000 in the third quarter of
2014 and increased 16% from pro forma revenues from solid tumor
testing services of $983,000 in the second quarter of 2015. Within
solid tumor testing services, the Company’s Cancer Origin Test posted
revenue of $346,000, a 27% increase compared with $273,000 in the
third quarter of 2014, and a 5% increase compared with $329,000 in the
second quarter of 2015.

Revenue from urologic cancer testing services in the third quarter of
2015 was $1.3 million, a 17% increase compared with pro forma urologic
cancer testing services revenues of $1.1 million in the second quarter
of 2015. Prior to the PersonalizeDx acquisition in April 2015, Rosetta
Genomics did not have revenue from urologic cancer testing services so
there is no comparison with the prior-year’s third quarter.

Gross billings for the third quarter of 2015 were $7.5 million
compared with gross billings of $644,000 in the third quarter of 2014.

Cost of revenues for the third quarter of 2015 were $2.2 million
compared with $377,000 for the same period in 2014.

Research and development expenses for the third quarter of 2015
increased to $586,000 from $482,000 in the third quarter of 2014.

Marketing and business development expenses for the third quarter of
2015 were $1.7 million compared with $1.6 million in the year-ago
period.

General and administrative expenses for the third quarter of 2015 were
$1.9 million compared with $1.3 million for the third quarter of 2014.

The operating loss for the third quarter of 2015 was $3.9 million,
including $211,000 of non-cash stock-based compensation expense,
compared with an operating loss of $3.4 million, including $264,000 of
non-cash stock-based compensation, for the third quarter of 2014.

The net loss for the third quarter of 2015 was $3.9 million, or $0.27
per ordinary share on 14.8 million shares outstanding, compared with a
net loss for the third quarter of 2014 of $3.4 million, or $0.29 per
ordinary share on 11.6 million shares outstanding.

For the nine months ended September 30, 2015, recorded revenues from
continuing operations were $4.7 million, an increase of 469% compared
with $827,000 for the same period of 2014.

Pro forma consolidated revenues for the first nine months of 2015,
assuming a full nine months of PersonalizeDx operations, were $6.6
million.

Revenue from solid tumor testing services in the first nine months of
2015 increased 196% to $2.5 million. Within solid tumor testing
services, the Company’s Cancer Origin Test posted revenue of $1.0
million during the first nine months of 2015, an increase of 25%
compared with $827,000 in the same period of 2014.

Revenue from urologic cancer testing services in the first nine months
of 2015 were $2.3 million. On a pro forma basis, urologic cancer
testing services in the first nine months of 2015 were $3.7 million.
As noted previously, prior to the PersonalizeDx acquisition in April
2015, Rosetta Genomics did not have revenue from urologic cancer
testing services so there is no comparison with the prior-year period.
Pro forma gross billings for the first nine months of 2015, assuming a
full nine months of PersonalizeDx operations, were $19.3 million,
which included gross billings for the PersonalizeDx business of $17.2
million. For the same period in 2014, Rosetta Genomics’ gross billings
were $2.0 million.

Cost of revenues for the first nine months of 2015 increased to $4.4
million from $1.1 million a year ago, primarily due to the
acquisition of PersonalizeDx leading to a higher volume of processed
samples as well as increases in personnel and infrastructure.

Research and development expenses for the first nine months of 2015
increased to $1.9 million from $1.5 million for the first nine months
of 2014, primarily due to increased activities related to the
development of the Company’s thyroid assay.

Marketing and business development expenses for the first nine months
of 2015 increased to $5.8 million from $4.9 million in the prior-year
period due to a larger commercial footprint as a result of the
acquisition of PersonalizeDx.

General and administrative expenses for the first nine months of 2015
were $5.5 million compared with $3.9 million for the same period in
2014, with the increase primarily due to acquisition-related costs of
the PersonalizeDx business.

The operating loss for the nine months ended September 30, 2015 was
$10.6 million, including $755,000 of non-cash stock-based compensation
expense as well as a $2.4 million gain from a bargain purchase related
to the acquisition of PersonalizeDx. This compares with an operating
loss for the first nine months of 2014 of $10.7 million, including
$735,000 of non-cash stock-based compensation expense.

The net loss for the first nine months of 2015 was $10.6 million, or
$0.76 per ordinary share on 14.0 million shares outstanding, compared
with a net loss for the same period in 2014 of $10.5 million, or $0.95
per ordinary share on 11.1 million shares outstanding.

Balance Sheet Highlights

As of September 30, 2015, Rosetta Genomics had $10.3 million in cash and
cash equivalents, restricted cash and short- and long-term bank
deposits, compared with $14.5 million as of June 30, 2015. The Company
used approximately $4.2 million in cash to fund operations during the
third quarter 2015. On October 16, 2015, Rosetta Genomics raised net
proceeds of $7.4 million in a private placement of units that consisted
of common shares and warrants. Given this recent fundraise and based on
the Company’s current operations and plans, Rosetta expects its current
cash position will fund operations into the first quarter of 2017.

Use of Non-GAAP Financial Measures

This press release contains certain non-GAAP financial measures. A
"non-GAAP financial measure" refers to a numerical measure of historical
or future financial performance, financial position or cash flows that
excludes (or includes) amounts that are included in (or excluded from)
the most directly comparable measure calculated and presented in
accordance with GAAP in the financial statements. In this news release,
Rosetta provides non-GAAP gross billings data as additional information
relating to its operating results. The presentation of this additional
information is not meant to be considered in isolation or as a
substitute for revenues, net loss or net loss per share prepared in
accordance with GAAP.

Pursuant to the requirements of Regulation G promulgated by the SEC, the
Company has provided a reconciliation of each non-GAAP financial measure
used in this earnings release and related conference call or webcast to
the most directly comparable financial measure prepared in accordance
with GAAP. This reconciliation is presented in the tables below under
the heading "Reconciliation of GAAP to Non-GAAP Consolidated Statement
of Operation." Investors are encouraged to review these reconciliations
to ensure they have a thorough understanding of the reported non-GAAP
financial measures and their most directly comparable GAAP financial
measures.

Management uses these non-GAAP measures for internal reporting and
forecasting purposes. The Company has provided these non-GAAP financial
measures in addition to GAAP financial results because it believes that
these non-GAAP financial measures provide useful information to certain
investors and financial analysts for comparison across accounting
periods not influenced by certain non-cash items that are not used by
management when evaluating the Company's historical and prospective
financial performance.

About RosettaGX Cancer Testing Services

RosettaGX Cancer Tests are a series of microRNA-based and other
molecular diagnostic testing services offered by Rosetta Genomics.
RosettaGX Cancer Origin™ can accurately identify the primary tumor type
in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). The mi-LUNG™ assay accurately identifies the
four main subtypes of lung cancer using small amounts of tumor cells.
The mi-KIDNEY™ assay accurately classifies the four most common kidney
tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. RosettaGX Reveal™, is a
first-of-its-kind microRNA-based assay for the classification of
indeterminate thyroid nodules. Rosetta’s assays are designed to provide
objective diagnostic data. In the U.S. alone, Rosetta Genomics estimates
that 150,000 patients a year may benefit from the RosettaGX Cancer
Origin test, 62,000 patients a year from the mi-KIDNEY assay, 222,000
patients a year from the mi-LUNG assay and 150,000 patients a year from
RosettaGX Reveal™ for indeterminate thyroid FNAs. The Company’s assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. With the acquisition of PersonalizeDx in
April 2015, the Company now offers a broader menu of molecular and other
assays for bladder, lung, prostate and breast cancer patients. For more
information, please visit www.rosettagx.com.
Parties interested in ordering any of these tests can contact Rosetta
Genomics at (215) 382-9000.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and
other molecular diagnostics. Rosetta’s integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has
led to the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full range of
microRNA-based diagnostic tools. Through the acquisition of
PersonalizeDx, the Company offers core FISH, IHC and PCR-based testing
capabilities and partnerships in oncology and urology that provide
additional content and platforms that complement the Rosetta offerings.
Rosetta’s and PersonalizeDx’s cancer testing services are commercially
available through the Philadelphia, PA- and Lake Forest, CA-based
CAP-accredited, CLIA-certified labs, respectively. For more information
visit www.rosettagx.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including but not limited
to statements that we expect RosettaGX Reveal to gain significant
traction into a market valued at $350 million annually in the U.S., that
the biomarker for which we were granted a patent allowance could be used
as both a prognostic tool and as a therapeutic target for prostate
cancer, that the recent CLFS and other favorable fee schedules are
encouraging and should continue to enhance both the amount and timing of
payments for our testing services in 2016 and that our current cash
position will fund operations into the first quarter of 2017constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section
of Rosetta’s Annual Report on Form 20-F for the year ended December 31,
2014 as filed with the SEC. In addition, any forward-looking statements
represent Rosetta’s views only as of the date of this release and should
not be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any forward-looking
statements unless required by law.